NYSE:GKOSMedical Equipment
How Glaukos’ Reaffirmed 2026 Sales Guidance and iDose TR Momentum Will Impact Glaukos (GKOS) Investors
Glaukos Corporation recently reaffirmed its 2026 net sales guidance of US$600 million to US$620 million after reporting strong preliminary, unaudited net sales for the fourth quarter and full year of 2025.
The company underscored its progress commercializing iDose TR and other glaucoma therapies, supported by a cash balance of US$283 million and no debt, which reinforces its capacity to fund ongoing product expansion.
We’ll now examine how Glaukos’ reaffirmed 2026 revenue guidance shapes the...